| Subject |
A US patent titled "Biomarkers for lung cancer stem cells" has been granted |
- Date of occurrence of the event: 2024/09/27
- Company name: ONENESS BIOTECH CO., LTD.
- Relationship to the Company (please enter ”head office” or ”subsidiaries”): head office
- Reciprocal shareholding ratios: NA
- Cause of occurrence: The Company has been informed by the patent agency that a United States patent titled “BIOMARKERS FOR LUNG CANCER STEM CELLS” has been granted under the patent number US 12,085,570 B2.
- Countermeasures: None.
- Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
- (1)This patent is for biomarkers for lung cancer stem cells which could be applied to cancer diagnosis and target patient screening. In addition, the expression of such biomarkers had been demonstrated to correlate with the prognosis of the patients, which predict the survival and recurrence in patents with the lung cancer.
- (2)The patent is owned by National Taiwan University. Oneness has been exclusively authorized to use this patent and to manufacture, use and sell the products of this invention.
|
